XGN · Exagen Inc. Common Stock
View on chartInsiders & Stakes
| NMSIC Co-Investment Fund, L.P. | ▼ Sell | Open Market | 1,758,958 Shares held | 3/25/2025 | View profile |
| James L. L. Tullis 10% Owner | ▲ Buy | Open Market | 1,515,839 Shares held | 6/15/2023 | View profile |
| ABALLI JOHN President and CEO | ▲ Buy | Grant | 839,834 Shares held | 3/12/2026 | View profile |
| Black Jeffrey G. Chief Financial Officer | ▲ Buy | Grant | 324,910 Shares held | 9/1/2026 | View profile |
| Adawi Kamal CFO and Corporate Secretary | ▼ Sell | Open Market | 243,749 Shares held | 3/4/2024 | View profile |
| Hazeltine Mark Chief Operating Officer | ▼ Sell | Open Market | 190,205 Shares held | 3/2/2023 | View profile |
| Rocca Fortunato R. President and CEO | ▼ Sell | Tax Withholding | 120,678 Shares held | 3/1/2022 | View profile |
| Zack Debra Chief Medical Officer | ▼ Sell | Tax Withholding | 84,259 Shares held | 3/1/2022 | View profile |
| Johnson Wendy S. Director | ▲ Buy | Open Market | 1,000 Shares held | 9/3/2021 | View profile |
Transaction History
| Black Jeffrey G. | ▼ Sell | Open Market | 20,614 | $149K | 9/1/2026 |
| Black Jeffrey G. | ▲ Buy | Grant | 1,571 | $5K | 9/1/2026 |
| Black Jeffrey G. | ▲ Buy | Grant | 75,000 | $237K | 3/12/2026 |
| ABALLI JOHN | ▲ Buy | Grant | 150,000 | $0 | 3/12/2026 |
| ABALLI JOHN | ▼ Sell | Open Market | 15,698 | $57K | 3/3/2026 |
| ABALLI JOHN | ▲ Buy | Grant | 2,535 | $8K | 3/3/2026 |
| Black Jeffrey G. | ▲ Buy | Grant | 1,511 | $5K | 2/27/2026 |
| ABALLI JOHN | ▼ Sell | Open Market | 11,430 | $41K | 2/24/2026 |
| Black Jeffrey G. | ▼ Sell | Open Market | 1,584 | $6K | 2/24/2026 |
| ABALLI JOHN | ▼ Sell | Open Market | 31,787 | $376K | 10/16/2025 |
| Black Jeffrey G. | ▼ Sell | Open Market | 20,466 | $200K | 9/2/2025 |
| NMSIC Co-Investment Fund, L.P. | ▼ Sell | Open Market | 350,000 | $1.2M | 3/25/2025 |
| ABALLI JOHN | ▲ Buy | Grant | 8,621 | $21K | 2/28/2025 |
| Black Jeffrey G. | ▲ Buy | Grant | 15,000 | $0 | 2/21/2025 |
| ABALLI JOHN | ▲ Buy | Grant | 112,500 | $0 | 2/21/2025 |
| NMSIC Co-Investment Fund, L.P. | ▼ Sell | Open Market | 200,000 | $660K | 11/20/2024 |
| Black Jeffrey G. | ▲ Buy | Open Market | 22,298 | $66K | 11/15/2024 |
| ABALLI JOHN | ▲ Buy | Open Market | 24,305 | $68K | 11/14/2024 |
| Black Jeffrey G. | ▲ Buy | Grant | 225,000 | $0 | 9/1/2024 |
| ABALLI JOHN | ▲ Buy | Open Market | 40,401 | $78K | 5/16/2024 |
| Adawi Kamal | ▼ Sell | Open Market | 9,297 | $18K | 3/4/2024 |
| Adawi Kamal | ▼ Sell | Open Market | 3,487 | $7K | 3/4/2024 |
| ABALLI JOHN | ▲ Buy | Grant | 9,804 | $19K | 2/29/2024 |
| Adawi Kamal | ▲ Buy | Grant | 75,000 | $0 | 2/20/2024 |
| ABALLI JOHN | ▲ Buy | Grant | 175,000 | $0 | 2/20/2024 |
| Adawi Kamal | ▼ Sell | Open Market | 6,738 | $13K | 2/6/2024 |
| ABALLI JOHN | ▼ Sell | Open Market | 33,819 | $59K | 10/17/2023 |
| ABALLI JOHN | ▲ Buy | Grant | 9,803 | $21K | 8/31/2023 |
| James L. L. Tullis | ▲ Buy | Open Market | 167 | $519 | 6/15/2023 |
| Adawi Kamal | ▼ Sell | Open Market | 3,667 | $8K | 3/2/2023 |
| Hazeltine Mark | ▼ Sell | Open Market | 3,667 | $0 | 3/2/2023 |
| Adawi Kamal | ▲ Buy | Grant | 100,000 | $0 | 2/27/2023 |
| Hazeltine Mark | ▲ Buy | Grant | 100,000 | $0 | 2/27/2023 |
| Hazeltine Mark | ▼ Sell | Open Market | 5,821 | $16K | 2/8/2023 |
| Adawi Kamal | ▼ Sell | Open Market | 5,821 | $16K | 2/8/2023 |
| ABALLI JOHN | ▲ Buy | Open Market | 90,000 | $241K | 12/8/2022 |
| ABALLI JOHN | ▲ Buy | Grant | 350,000 | $0 | 10/16/2022 |
| Zack Debra | ▼ Sell | Tax Withholding | 3,241 | $23K | 3/1/2022 |
| Hazeltine Mark | ▼ Sell | Tax Withholding | 3,241 | $23K | 3/1/2022 |
| Adawi Kamal | ▼ Sell | Tax Withholding | 3,241 | $23K | 3/1/2022 |
| Rocca Fortunato R. | ▼ Sell | Tax Withholding | 4,322 | $31K | 3/1/2022 |
| Hazeltine Mark | ▲ Buy | Grant | 63,500 | $0 | 2/4/2022 |
| Adawi Kamal | ▲ Buy | Grant | 63,500 | $0 | 2/4/2022 |
| Zack Debra | ▲ Buy | Grant | 50,000 | $0 | 2/4/2022 |
| Rocca Fortunato R. | ▲ Buy | Grant | 75,000 | $0 | 2/4/2022 |
| Johnson Wendy S. | ▲ Buy | Open Market | 1,000 | $14K | 9/3/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
TD Cowen Raises Exagen Price Target to $11
TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.
TD Cowen Raises Exagen Price Target to $11. TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.